沃诺拉赞与幽门螺杆菌根除后胃癌风险的相关性
本研究基于日本人群索赔数据库,纳入2015至2018年间接受克拉霉素为基础首次幽门螺杆菌根除方案的患者,排除失败及根除前或根除后1年内诊断胃癌者。经倾向评分匹配比较钾竞争性酸阻滞剂(PCAB,本研究中仅沃诺拉赞)使用者与H2受体拮抗剂使用者的胃癌发生率。
要点
- PCAB(沃诺拉赞)使用与幽门螺杆菌根除后胃癌风险升高相关,匹配风险比1.92。
- PCAB使用疗程更长、剂量更高者胃癌发生率更高。
- 敏感性分析显示PCAB使用者胃癌风险与PPI使用者相当。
核心结论
- 在幽门螺杆菌根除患者中,PCAB(沃诺拉赞)使用与胃癌风险增加相关,且存在疗程和剂量反应效应。
研究设计与样本
- 基于日本人群索赔数据库的回顾性队列研究,纳入2015至2018年间接受克拉霉素为基础首次幽门螺杆菌根除方案的患者。
- 排除根除失败者及根除前或根除后1年内诊断胃癌者,共纳入54,055例患者。
- 采用倾向评分匹配比较PCAB使用者与H2受体拮抗剂使用者的胃癌发生率,匹配因素包括年龄、性别、吸烟、饮酒、合并症及合并用药。
- 本研究中PCAB仅指沃诺拉赞。
主要发现
- 中位随访3.65年期间,568例(1.05%)发生胃癌。
- PCAB使用者胃癌累积发生率3年为1.64%、4年为2.02%、5年为2.36%;H2受体拮抗剂使用者分别为3年0.71%、4年1.04%、5年1.22%。
- 更长疗程和更高剂量PCAB使用与胃癌发生率更高显著相关。
- 敏感性分析显示PCAB使用者胃癌发生风险与PPI使用者相当。
临床怎么用
- 在幽门螺杆菌根除后患者中处方沃诺拉赞时,需权衡胃癌风险,尤其对需长期或高剂量使用者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Potassium-competitive acid blockers (PCABs) have been increasingly used to treat upper gastrointestinal disorders, replacing proton pump inhibitors (PPIs). Whereas PPIs are associated with an increased risk of gastric cancer (GC) after Helicobacter pylori (Hp) eradication, it is uncertain whether PCABs carry the same risk. METHODS: Using a population-based claims database in Japan, we identified patients who were prescribed a clarithromycin-based first regimen of Hp eradication between 2015 and 2018. Patients who failed this regimen and those diagnosed with GC before or within 1 year after Hp eradication were excluded. We compared GC incidence between PCAB users and histamine type-2 receptor antagonist (H2RA) users, matching them on the basis of propensity scores calculated with considerations for age, sex, smoking, alcohol consumption, comorbidities, and co-administered medications. PCABs included only vonoprazan in this study. RESULTS: Among 54,055 patients, 568 (1.05%) developed GC during the follow-up period (mean, 3.65 years). The cumulative incidence of GC was 1.64% at 3 years, 2.02% at 4 years, and 2.36% at 5 years in PCAB users and 0.71% at 3 years, 1.04% at 4 years, and 1.22% at 5 years in H2RA users. The use of PCABs was associated with a higher GC risk (matched hazard ratio, 1.92; 95% confidence interval, 1.13-3.25; P = .016). Longer PCAB use and high-dose PCAB use were significantly associated with higher incidence of GC. Sensitivity analyses showed the risk of GC incidence among PCAB users was comparable with that of PPI users. CONCLUSIONS: The use of PCABs was associated with an increased risk of GC among Hp-eradicated patients, with duration/dose response effects.
引用
- Arai J, Miyawaki A, Aoki T, et al. Association Between Vonoprazan and the Risk of Gastric Cancer After Helicobacter pylori Eradication. Clin Gastroenterol Hepatol. 2024. PMID: 38354970. doi:10.1016/j.cgh.2024.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。